These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 35429281

  • 1. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
    van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M.
    Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups.
    Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
    Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh J.
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
    [Abstract] [Full Text] [Related]

  • 4. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
    Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J, COAST-X Study Group.
    Lancet; 2020 Jan 04; 395(10217):53-64. PubMed ID: 31813637
    [Abstract] [Full Text] [Related]

  • 5. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
    Deodhar AA, Mease PJ, Rahman P, Navarro-Compán V, Strand V, Hunter T, Bolce R, Leon L, Lauzon S, Marzo-Ortega H.
    BMC Rheumatol; 2021 Sep 20; 5(1):35. PubMed ID: 34538257
    [Abstract] [Full Text] [Related]

  • 6. Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial.
    Deodhar A, Mease P, Rahman P, Navarro-Compán V, Marzo-Ortega H, Hunter T, Sandoval D, Kronbergs A, Leon L, Shan M, Leung A, De Vlam K, Strand V.
    Rheumatol Ther; 2021 Mar 20; 8(1):135-150. PubMed ID: 33284423
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
    van der Heijde D, Østergaard M, Reveille JD, Baraliakos X, Kronbergs A, Sandoval DM, Li X, Carlier H, Adams DH, Maksymowych WP.
    J Rheumatol; 2022 Mar 20; 49(3):265-273. PubMed ID: 34853086
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
    Baraliakos X, Deodhar A, van der Heijde D, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Fleurinck C, Ellis AM, Vaux T, Shepherd-Smith J, Marten A, Gensler LS.
    Ann Rheum Dis; 2024 Jan 11; 83(2):199-213. PubMed ID: 37793792
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
    van der Heijde D, Baraliakos X, Hermann KA, Landewé RBM, Machado PM, Maksymowych WP, Davies OR, de Peyrecave N, Hoepken B, Bauer L, Nurminen T, Braun J.
    Ann Rheum Dis; 2018 May 11; 77(5):699-705. PubMed ID: 29343510
    [Abstract] [Full Text] [Related]

  • 18. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A.
    Rheumatology (Oxford); 2017 Sep 01; 56(9):1498-1509. PubMed ID: 28498975
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewé RBM, Ramiro S, van der Heijde D, Nikiphorou E.
    Ann Rheum Dis; 2023 Jan 01; 82(1):130-141. PubMed ID: 36270657
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
    Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD, COAST-W Study Group.
    Arthritis Rheumatol; 2019 Apr 01; 71(4):599-611. PubMed ID: 30343531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.